1. Matthew, Elizabeth M, Yang, Zhaohai, Peri, Suraj, Ross, Eric, El-Deiry, Wafik S. 2018. Plk2 Loss Commonly Occurs in Colorectal Carcinomas but not Adenomas: Relationship to mTOR Signaling. In Neoplasia (New York, N.Y.), 20, 244-255. doi:10.1016/j.neo.2018.01.004. https://pubmed.ncbi.nlm.nih.gov/29448085/
2. Wei, Xiaona, Wu, Jianping, Li, Jiajia, Yang, Qiongqiong. 2022. PLK2 targets GSK3β to protect against cisplatin-induced acute kidney injury. In Experimental cell research, 417, 113181. doi:10.1016/j.yexcr.2022.113181. https://pubmed.ncbi.nlm.nih.gov/35523306/
3. Berg, Tobias, Bug, Gesine, Ottmann, Oliver G, Strebhardt, Klaus. 2012. Polo-like kinases in AML. In Expert opinion on investigational drugs, 21, 1069-74. doi:10.1517/13543784.2012.691163. https://pubmed.ncbi.nlm.nih.gov/22667760/
4. Cheng, Junjie, Wu, Lei, Chen, Xiaowan, Zhen, Xuechu, Zheng, Long-Tai. 2024. Polo-like kinase 2 promotes microglial activation via regulation of the HSP90α/IKKβ pathway. In Cell reports, 43, 114827. doi:10.1016/j.celrep.2024.114827. https://pubmed.ncbi.nlm.nih.gov/39383034/